Gynecologic Oncology Reports · 2022 · 17 citations · 11 references
MedicineOncologyPharmacologyGynecologic OncologyMetastasisMolecular OncologyCancer Cell SignalingCancer Molecular PathologyMalignant NeoplasmsNext-generation Sequencing In OncologySynthetic LethalityUterine LeiomyomaBrca MutationsDisease-free Survival AnalysisDisease-free Survival AssessmentLeiomyosarcoma TherapyOlaparib TherapyParp InhibitionRecurrent Disease TherapySomatic Mutations
Uterine leiomyosarcoma (uLMS) is an aggressive mesenchymal tumor associated with a poor prognosis. Research demonstrates that PARP inhibitors (PARPi) improve disease-stable survival in patients with somatic BRCA1/2 mutations through the process of synthetic lethality. Therefore, PARPi’s may have a role in treating gynecologic malignancies with deleterious BRCA1/2 mutations. This patient is a 50-year-old female with a history of stage IB uterine leiomyosarcoma, complicated by recurrence along the vaginal cuff and metastases to the lungs. A somatic BRCA2 mutation was identified, and the patient was started on Olaparib for treatment of recurrent disease. The patient has now been disease free for two years. We recommend next generation sequencing be performed to identify functional BRCA1/2 loss in uLMS as PARPi may be a potential targeted therapy for uLMS.
11
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Helen E. Bryant, Niklas Schultz, Huw D. Thomas et al. · Nature · 2005 · 5.2K citations
Nicholas Reed, Costantino Mangioni, Henric Malmström et al. · European Journal of Cancer · 2008 · 531 citations